Cargando…
CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer
BACKGROUND: Cervical cancer is the third most common gynecological malignancy. Conventional treatment options are known to be ineffective for the majority of patients with advanced or recurrent cervical cancer. Therefore, novel therapeutic agents for cervical cancer are necessary. In this study, the...
Autores principales: | Lee, Sungha, Ho, Jung Yoon, Liu, Jing Jing, Lee, Hyewon, Park, Jae Young, Baik, Minwha, Ko, Minji, Lee, Seon Ui, Choi, Youn Jin, Hur, Soo Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540464/ https://www.ncbi.nlm.nih.gov/pubmed/31138113 http://dx.doi.org/10.1186/s10020-019-0089-y |
Ejemplares similares
-
Anticancer effects of CKD-602 (Camtobell(®)) via G2/M phase arrest in oral squamous cell carcinoma cell lines
por: KIM, YOUNG-KYUN, et al.
Publicado: (2015) -
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients
por: Wu, Huali, et al.
Publicado: (2012) -
Completion of R602
por: CERN. Geneva. ISR Experiments Committee
Publicado: (1973) -
Who is who in R602
por: Baum, L, et al.
Publicado: (1973) -
Poster Sessions 602-806
Publicado: (2004)